keyword
MENU ▼
Read by QxMD icon Read
search

Hfpef

keyword
https://www.readbyqxmd.com/read/29684593/renal-function-n-terminal-pro-b-type-natriuretic-peptide-propeptide-big-endothelin-and-patients-with-heart-failure-and-preserved-ejection-fraction
#1
Ingrid Gergei, Bernhard K Krämer, Hubert Scharnagl, Tatjana Stojakovic, Winfried März
Renal dysfunction may limit the clinical application of NT-proBNP in the diagnosis of heart failure. In general practice, where echocardiography is not readily available, a biomarker for the diagnosis of a heart failure with preserved ejection fraction (HFpEF) would be useful. Since cardiac diseases frequently coincide with renal disease, there is a high need of valid risk stratification methods in patients affected with both. We therefore examined NT-proBNP and another biomarker, Big-Endothelin-1, as a marker of HFpEF in patients with CKD...
April 20, 2018: Peptides
https://www.readbyqxmd.com/read/29677191/type-2-diabetic-aldehyde-dehydrogenase-2-mutant-mice-aldh-2-2-exhibiting-heart-failure-with-preserved-ejection-fraction-phenotype-can-be-determined-by-exercise-stress-echocardiography
#2
Guodong Pan, Srikar Munukutla, Ananya Kar, Joseph Gardinier, Rajarajan A Thandavarayan, Suresh Selvaraj Palaniyandi
E487K point mutation of aldehyde dehydrogenase (ALDH) 2 (ALDH2*2) in East Asians intrinsically lowers ALDH2 activity. ALDH2*2 is associated with diabetic cardiomyopathy. Diabetic patients exhibit heart failure of preserved ejection fraction (HFpEF) i.e. while the systolic heart function is preserved in them, they may exhibit diastolic dysfunction, implying a jeopardized myocardial health. Currently, it is challenging to detect cardiac functional deterioration in diabetic mice. Stress echocardiography (echo) in the clinical set-up is a procedure used to measure cardiac reserve and impaired cardiac function in coronary artery diseases...
2018: PloS One
https://www.readbyqxmd.com/read/29667019/what-is-new-in-heart-failure-management-in-2017-update-on-acc-aha-heart-failure-guidelines
#3
REVIEW
Biykem Bozkurt
PURPOSE OF REVIEW: The goal of this paper is to provide a summary of the new recommendations in the most recent 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. The intent is to provide the background and the supporting evidence for the recommendations and to provide practical guidance for management strategies in treatment of heart failure patients...
April 17, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29664406/racial-differences-in-characteristics-and-outcomes-of-patients-with-heart-failure-and-preserved-ejection-fraction-in-the-treatment-of-preserved-cardiac-function-heart-failure-trial
#4
Eldrin F Lewis, Brian Claggett, Amil M Shah, Jiankang Liu, Sanjiv J Shah, Inder Anand, Eileen O'Meara, Nancy K Sweitzer, Jean L Rouleau, James C Fang, Akshay S Desai, Tamrat M Retta, Scott D Solomon, John F Heitner, Thomas D Stamos, Robin Boineau, Bertram Pitt, Marc A Pfeffer
BACKGROUND: Black patients have been shown to have different baseline characteristics and outcomes compared with nonblack patients in cohort studies. However, few studies have focused on heart failure (HF) with preserved ejection fraction (HFpEF) patients. We aimed to determine the difference in cardiovascular outcomes in black and nonblack patients with HFpEF and to determine the relative efficacy and safety of spironolactone in black and nonblack patients. METHODS AND RESULTS: Patients with HFpEF, randomized to spironolactone versus placebo in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) in North and South America, were grouped according to self-described black and nonblack race...
March 2018: Circulation. Heart Failure
https://www.readbyqxmd.com/read/29663123/creation-of-a-restrictive-atrial-communication-in-heart-failure-with-preserved-and-mid-range-ejection-fraction-effective-palliation-of-left-atrial-hypertension-and-pulmonary-congestion
#5
Anna Bauer, Markus Khalil, Monika Lüdemann, Jürgen Bauer, Anoosh Esmaeili, Roberta De-Rosa, Norbert F Voelkel, Hakan Akintuerk, Dietmar Schranz
BACKGROUND: Left atrial decompression is considered in patients with symptomatic heart failure with preserved ejection fraction (HFpEF). We aimed to evaluate the feasibility and efficacy of transcatheter generation of a restrictive atrial septum communication to manage HFpEF from infancy to adulthood with cardiomyopathy and congenital heart defect. METHODS AND RESULTS: From June 2009 to December 2016, 24 patients (50% with an age less than 16 years) with HFpEF were palliated; NYHA-/Ross class IV (n = 10); median systemic ventricular ejection fraction 64 (range 35-78) %...
April 16, 2018: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/29661795/machine-learning-analysis-of-left-ventricular-function-to-characterize-heart-failure-with-preserved-ejection-fraction
#6
Sergio Sanchez-Martinez, Nicolas Duchateau, Tamas Erdei, Gabor Kunszt, Svend Aakhus, Anna Degiovanni, Paolo Marino, Erberto Carluccio, Gemma Piella, Alan G Fraser, Bart H Bijnens
BACKGROUND: Current diagnosis of heart failure with preserved ejection fraction (HFpEF) is suboptimal. We tested the hypothesis that comprehensive machine learning (ML) of left ventricular function at rest and exercise objectively captures differences between HFpEF and healthy subjects. METHODS AND RESULTS: One hundred fifty-six subjects aged >60 years (72 HFpEF+33 healthy for the initial analyses; 24 hypertensive+27 breathless for independent evaluation) underwent stress echocardiography, in the MEDIA study (Metabolic Road to Diastolic Heart Failure)...
April 2018: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29661477/low-diastolic-blood-pressure-and-adverse-outcomes-in-heart-failure-with-preserved-ejection-fraction
#7
Tetsuro Tsujimoto, Hiroshi Kajio
BACKGROUND: It remains unknown whether a low diastolic blood pressure (DBP) increases the risks of cardiovascular events and death in patients with heart failure with preserved ejection fraction (HFpEF). METHODS: We used data from the TOPCAT trial. The primary outcome was a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure. Hazard ratios (HRs) were analyzed for DBPs of <60, 60-69, 70-79, and ≥90 mm Hg in comparison with a DBP of 80-89 mm Hg using multivariable Cox proportional hazard models...
April 9, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29660263/characteristics-and-long-term-prognosis-of-patients-with-heart-failure-and-mid-range-ejection-fraction-compared-with-reduced-and-preserved-ejection-fraction-a-systematic-review-and-meta-analysis
#8
Josephine Lauritsen, Finn Gustafsson, Jawdat Abdulla
AIMS: This study aimed to assess by a meta-analysis the clinical characteristics, all-cause and cardiovascular mortality, and hospitalization of patients with heart failure (HF) with mid-range ejection fraction (HFmrEF) compared with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). METHODS AND RESULTS: Data from 12 eligible observational studies including 109 257 patients were pooled. HFmrEF patients were significantly different and occupied a mid-position between HFrEF and HFpEF: mean age 73...
April 16, 2018: ESC Heart Failure
https://www.readbyqxmd.com/read/29659727/nitrite-circumvents-platelet-resistance-to-nitric-oxide-in-patients-with-heart-failure-preserved-ejection-fraction-and-chronic-atrial-fibrillation
#9
Alessandra Borgognone, Eduard Shantsila, Sophie M Worrall, Eakkapote Prompunt, Thomas Loka, Brodie L Loudon, Myriam Chimen, G Ed Rainger, Janet M Lord, Ashley Turner, Peter Nightingale, Martin Feelisch, Paulus Kirchhof, Gregory Y H Lip, Steve P Watson, Michael P Frenneaux, Melanie Madhani
Aims: Heart failure (HF) is a pro-thrombotic state. Both platelet and vascular responses to nitric oxide (NO) donors are impaired in HF patients with reduced ejection fraction (HFrEF) compared to healthy volunteers (HV) due to scavenging of NO, and possibly also reduced activity of the principal NO sensor, soluble guanylate cyclase (sGC), limiting the therapeutic potential of NO donors as anti-aggregatory agents. Previous studies have shown that nitrite inhibits platelet activation presumptively after its reduction to NO, but the mechanism(s) involved remain poorly characterized...
April 12, 2018: Cardiovascular Research
https://www.readbyqxmd.com/read/29657034/cost-comparison-across-heart-failure-patients-with-reduced-and-preserved-ejection-fractions-analyses-of-inpatient-decompensated-heart-failure-admissions
#10
Natalia Olchanski, Amanda R Vest, Joshua T Cohen, Peter J Neumann, David DeNofrio
BACKGROUND: Heart failure (HF) is the leading cause of inpatient admissions in the US for adults aged over 65 years and accounts for more than $17 billion in Medicare expenditures annually. There are limited published data on factors influencing expenditure and the relationship between cost and hospital length of stay. We sought to describe institutional costs of HF hospitalization, as well as demographic and clinical predictors of higher hospitalization costs in an academic hospital setting...
June 15, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29656687/longitudinal-evaluation-of-ventricular-ejection-fraction-and-nt-probnp-across-heart-failure-subgroups
#11
Andreas Martinsson, Petter Oest, Maj-Britt Wiborg, Öyvind Reitan, J Gustav Smith
OBJECTIVES: Left ventricular ejection fraction (EF) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are important surrogate markers of cardiac function and wall stress. Randomized trials of heart failure (HF) have shown improvements in survival in patients with reduced EF (<40%, HFrEF) but not with preserved EF (≥50%, HFpEF) or mid-range EF (40-49%, HFmrEF). Limited information is available on the trajectory of EF in contemporary heart failure management programs (HFMPs)...
April 14, 2018: Scandinavian Cardiovascular Journal: SCJ
https://www.readbyqxmd.com/read/29655830/medicare-expenditures-by-race-ethnicity-after-hospitalization-for-heart-failure-with-preserved-ejection-fraction
#12
Boback Ziaeian, Paul A Heidenreich, Haolin Xu, Adam D DeVore, Roland A Matsouaka, Adrian F Hernandez, Deepak L Bhatt, Clyde W Yancy, Gregg C Fonarow
OBJECTIVES: The purpose of this study was to analyze cumulative Medicare expenditures at index admission and after discharge by race or ethnicity. BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a growing proportion of heart failure (HF) admissions. Research on health care expenditures for patients with HFpEF is limited. METHODS: Records of patients discharged from the Get With The Guidelines-Heart Failure registry between 2006 and 2014 were linked to Medicare data...
April 5, 2018: JACC. Heart Failure
https://www.readbyqxmd.com/read/29651826/new-percutaneous-interventions-in-heart-failure
#13
Elisabetta Moscarella, Salvatore Brugaletta, Manel Sabaté
Chronic heart failure (HF) is one of the main causes of mortality and morbidity worldwide and represents a growing challenge in interventional cardiology. Its prevalence is recently increasing due to the improvements in cardiac care with subsequent significant reduction in the HF acute mortality. HF may occur with either a reduced left ventricular ejection fraction (LVEF) (LVEF<40%, HFrEF) or a preserved EF (typically LVEF≥50%, HFpEF) indicative of diastolic dysfunction. Despite recent advances in drug therapies as well as in nonpharmacological strategies, including defibrillators, cardiac resynchronization therapy, LV assist devices (LVAD), mortality in HF remains high...
April 12, 2018: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/29650706/pro-inflammatory-biomarkers-in-stable-versus-acutely-decompensated-heart-failure-with-preserved-ejection-fraction
#14
Abraham Abernethy, Sadi Raza, Jie-Lena Sun, Kevin J Anstrom, Russell Tracy, Johannes Steiner, Peter VanBuren, Martin M LeWinter
BACKGROUND: Underlying inflammation has been increasingly recognized in heart failure with a preserved ejection fraction (HFpEF). In this study we tested the hypothesis that pro-inflammatory biomarkers are elevated in patients with acutely decompensated HFpEF (AD-HFpEF) compared with patients with stable HFpEF (S-HFpEF). METHODS AND RESULTS: Using a post hoc analysis the serum biomarkers tumor necrosis factor-alpha, high-sensitivity C-reactive protein interleukin 6 and pentraxin 3 (PTX3) and clinical, demographic, echocardiographic-Doppler and clinical outcomes data were analyzed in HFpEF patients enrolled in NHLBI Heart Failure Research Network clinical trials which enrolled patients with either AD-HFpEF or S-HFpEF...
April 12, 2018: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29625952/effects-of-dietary-inorganic-nitrate-supplementation-on-exercise-performance-in-patients-with-heart-failure-protocol-for-a-randomized-placebo-controlled-cross-over-trial
#15
Mary N Woessner, Itamar Levinger, Christopher Neil, Cassandra Smith, Jason D Allen
BACKGROUND: Chronic heart failure is characterized by an inability of the heart to pump enough blood to meet the demands of the body, resulting in the hallmark symptom of exercise intolerance. Chronic underperfusion of the peripheral tissues and impaired nitric oxide bioavailability have been implicated as contributors to the decrease in exercise capacity in these patients. nitric oxide bioavailability has been identified as an important mediator of exercise tolerance in healthy individuals, but there are limited studies examining the effects in patients with chronic heart failure...
April 6, 2018: JMIR Research Protocols
https://www.readbyqxmd.com/read/29623530/novel-insights-and-treatment-strategies-for-right-heart-failure
#16
REVIEW
Weiqin Lin, Ai-Ling Poh, W H Wilson Tang
PURPOSE OF REVIEW: The function of the right ventricle (RV) is intimately linked to its preload (systemic volume status) and afterload (pulmonary vasculature). In this review, we explore current knowledge in RV physiology, RV function assessment, causes of right heart failure (RHF), and specific treatment strategies for RHF. RECENT FINDINGS: We examine the evidence behind new pharmacological therapies available, such as macitentan and riociguat in the treatment of specific etiologies of RHF...
April 6, 2018: Current Heart Failure Reports
https://www.readbyqxmd.com/read/29622288/comparison-of-prognostic-usefulness-of-serum-insulin-like-growth-factor-binding-protein-7-in-patients-with-heart-failure-and-preserved-versus-reduced-left-ventricular-ejection-fraction
#17
Camilla Hage, Mette Bjerre, Jan Frystyk, Harvest F Gu, Kerstin Brismar, Erwan Donal, Jean-Claude Daubert, Cecilia Linde, Lars H Lund
We aimed to characterize of the role of insulin-like growth factor-binding protein 7 (IGFBP-7) in heart failure (HF) pathophysiology. IGFBP-7 has been associated with cardiac hypertrophy and diastolic dysfunction in HF. In 86 patients with HF with a preserved ejection fraction (HFpEF) (ejection fraction [EF] ≥45%) and 79 with HF with a reduced ejection fraction (HFrEF), we assessed concentrations of serum IGFBP-7, correlations between serum IGFBP-7 and clinical data, diastolic function, and associations with outcome...
March 14, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29620605/captopril-attenuates-cardiovascular-and-renal-disease-in-a-rat-model-of-heart-failure-with-preserved-ejection-fraction
#18
Eman M Salah, Sheldon I Bastacky, Edwin K Jackson, Stevan P Tofovic
Heart failure with preserved ejection fraction (HFpEF), a prevalent form of heart failure, is frequently accompanied by the metabolic syndrome and kidney disease. Because current treatment options of HFpEF are limited, evaluation of therapies in experimental models of HFpEF with the metabolic syndrome and kidney disease is needed. In this study, we evaluated the effects of captopril, furosemide, and their combination in aged, obese ZSF1 rats, an animal model of HFpEF with the metabolic syndrome and chronic kidney disease as comorbidities...
April 2018: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/29619838/relationship-between-exercise-intervention-and-no-pathway-in-patients-with-heart-failure-with-preserved-ejection-fraction
#19
Flavia Baldassarri, Edzard Schwedhelm, Dorothee Atzler, Rainer H Böger, Kathrin Cordts, Bernhard Haller, Axel Pressler, Stephan Müller, Christiane Suchy, Rolf Wachter, Hans-Dirk Düngen, Gerd Hasenfuss, Burkert Pieske, Martin Halle, Frank Edelmann, André Duvinage
OBJECTIVE: Elevated levels of arginine derivatives in the NO pathway, such as asymmetric dimethylarginine (ADMA), are related to disease severity and reduced exercise capacity in heart failure. We investigated the influence of exercise intervention on these parameters and on L-arginine (L-Arg) and L-homoarginine (L-hArg) in heart failure with preserved ejection fraction (HFpEF) patients. MATERIAL AND METHODS: Sixty-two patients (65 ± 6 years) were included in this analysis and randomised to supervised endurance/resistance training (ET) or to usual care (UC)...
April 5, 2018: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/29619635/the-role-of-arterial-hypertension-in-development-heart-failure-with-preserved-ejection-fraction-just-a-risk-factor-or-something-more
#20
REVIEW
Marijana Tadic, Cesare Cuspidi, Athanasios Frydas, Guido Grassi
Heart failure with preserved ejection fraction (HFpEF) is an entity that still raises many questions. The agreement about definition, pathophysiology, and therapeutic approach is still missing. Arterial hypertension is present in majority of patients with HFpEF, and it is still not clear if it represent a risk factor or "sine qua non" condition for HFpEF development. The underlying mechanisms of hypertension and HFpEF involve the same biohumoral systems: renin-angiotensin-aldosterone, sympathetic nervous system, and oxidative stress...
April 4, 2018: Heart Failure Reviews
keyword
keyword
6587
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"